Strong Rebound for PSKY as Bulls Test Key Resistance Levels
$Paramount Skydance Corp(PSKY)$ $16.74 (+9.77%) — Breakout Reversal Attempt: Watch $17.5–$18 for Trend ConfirmationParamount Skydance jumped +9.77% to $16.74, marking one of its strongest single-day rallies since early September. The surge came on volume of ~15.65M vs. 11.78M average, confirming genuine buying interest after several weeks of consolidation near $15. Drivers included bargain hunting ahead of earnings and renewed speculation over content licensing and streaming asset synergies. Year-to-date, PSKY is up +60.0%, outperforming the media/entertainment sector average.Technicals & 1-week viewVolume + MACD: momentum just turned positive—MACD (0.02) crossed above signal (-0.48), an early bullish inflection from deeply negative territory.
$Alphabet(GOOG)$ $291.74 (+0.40%) — Fresh 52-wk High Test: Momentum Builds, Eyes $295–$300Alphabet closed at $291.74, up 0.40%, now ~0.2% below its 52-week high $292.34 (new high intraday). YTD gain sits near +53% with volume (~14.1M) below the ~21.8M average—trend intact but not euphoric. Drivers today: (1) follow-through from Q3 beats with Search/YouTube resilience and Cloud profitability; (2) ongoing AI product cadence supporting multiple-expansion; (3) mega-cap bid as rates eased, lifting long-duration tech.Technicals & 1-week viewPrice holds a powerful up-channel above the EMA-20 ≈ $272.9 and EMA-50 ≈ $253.9; the short/medium trend remains decisively up. MACD is positive with a rising histogram—momentum continuation bias. RSI ~72–73 is ov
Oracle Weakens Under EMA Pressure, Testing $225 Zone
$Oracle(ORCL)$ $236.15 (-1.94%) — Cloud re-rating drags further; watch $225 support or risk breakdown toward $220Oracle closed at $236.15, down 1.94%, extending its multi-week decline as investors rotate out of enterprise software into high-growth AI and semiconductor names. The stock is now ~32% below its 52-week high ($345.72) but still +41.7% YTD, reflecting earlier cloud optimism. Volume came in at 20.3M vs 23.7M avg, consistent with a controlled selloff rather than panic. Weakness continues post-earnings as macro rate sensitivity and multiple compression weigh on large-cap tech.Technicals & 1-week viewVolume + MACD: momentum remains bearish—MACD line (-12.23) below signal (-8.18) with histogram still negative, showing no recovery attempt
$Rocket Lab USA, Inc.(RKLB)$ $51.24 (-1.27%) — Post-rally fatigue under EMA pressure; bulls need $55–58 reclaim for recoveryRocket Lab closed at $51.24, down 1.27%, extending its short-term pullback after the October peak near $74. Despite being up +101% YTD, the stock remains roughly 31% below its 52-week high ($73.97). Volume rose to ~32.24M vs 22.4M avg, signaling distribution rather than accumulation. The day’s weakness reflected continued risk-off flow across high-beta growth and aerospace names, alongside soft investor sentiment in small-cap techs.Technicals & 1-week viewVolume + MACD: histogram negative (–1.99 vs –1.56 signal), but flattening—momentum may be stabilizing. RSI (14) at 38.5 hovers in lower-neutral, hinting at mild oversold
$BigBear.ai Holdings(BBAI)$ $6.06 (+6.13%) — Oversold Rebound in Progress, Testing EMA Resistance at $6.5–6.6BigBear.ai Holdings climbed +6.13% to $6.06, recovering from its late-October dip near $5.70 as buyers stepped in around support. The rally follows renewed retail interest in AI-linked defense software stocks, adding to a year-to-date gain of +36.2%. Momentum remains fragile, however, as price action continues below key moving averages.Technicals (1-week outlook)Price has rebounded but remains below both EMA-20 ($6.48) and EMA-50 ($6.56), forming a short-term resistance zone.MACD (12,26,9): –0.142 vs signal –0.323 (histogram +0.18) — bearish momentum fading; a crossover could trigger fresh upside.RSI (14): 43.6, rising from oversold levels
🎉🎉Congrats to Weekly Top 5 Most Active & Promising CBA Traders!💰💰
Hey SG Tigers!🐯Another week has gone by, and we are happy to see many amazing tradings from you!🎉🎉🎉Here we present the top 5 most active/promising Cash Boost Account (CBA) traders for the week of November 3rd-7th!🎉🎉We'd like to congratulate @hbbj@Niofighter@jeevanthomas@keithfx@SHLim@6d054508@moonrocket@皇家百万基金
Earnings Movers | CRWV Cut Guidance, Oversold or Not?
1. $CoreWeave, Inc.(CRWV)$ plunged 16.31%Revenue: $1.37B vs. $1.28B expected (+7% beat)Adjusted EPS: −$0.22 vs. −$0.36 expected (+38.9% beat)Outlook: FY2025 Revenue expects $5.05B–$5.15B (down from $5.15B–$5.35B), Adjusted Operating Income to be $690M–$720M (down from $800M–$830M), Capex to be $12B–$14B (cut from $20B–$23B) due to data center delays.CRWV shares fell after the company reduced its guidance, citing a delay at one of its third-party data center providers. Despite the adverse investor reaction, retail traders’ sentiment toward CoreWeave stock improved appreciably following the quarterly print.CoreWeave CEO Michael Intrator said, “Our performance reflects disciplined execution across every part of our business, from scaling infrastructu
💥"Pharma Heaven & Hell": MRK & AMGN Lead Dow, LLY Hits ATH, Health Insurance Plunges
[Allin]Hey~Tigers: The pharma sector is currently experiencing a "heaven and hell" divergence. On one side, $Merck(MRK)$ and $Amgen(AMGN)$ enjoy safe-haven premiums, $Eli Lilly(LLY)$ hits new highs on GLP-1 deal certainty; on the other side, health insurance faces a business model collapse due to Trump's "direct subsidy payment" rhetoric. Investors must watch policy signals closely to avoid walking a tightrope between innovative drug dividends and policy risks.This article focuses on:Market Overview: Dow Hits New High, Pharma Sector EmergesGLP-1 Weight Loss Drug Market Upheaval: Government Price-Cut Deal Impacts Lilly, Novo Nordisk Competitive LandscapeTrump's Comm
AMD Surges 96% in 2025: How will it go under $1 Trillion vision?
Abstract:At AMD’s first Analyst Day in three years held on November 11th $Advanced Micro Devices(AMD)$ , the company sent a major signal: the data center chip market will reach $1 trillion by 2030, with the firm targeting a revenue compound annual growth rate (CAGR) of over 35% and earnings per share (EPS) of $20 over the next 3-5 years.AI_DigAMD’s Financial Analyst Day in New York on November 11th was more than just its first appearance in three years—it was like a declaration of war against industry leader Nvidia $NVIDIA(NVDA)$ . During the event, CEO Lisa Su shared optimistic expectations for the artificial intelligence (AI) market and announced AMD’s financial goals for the next three to five years. Sh
$Amazon.com(AMZN)$ 's "dual-engine" is firing! E-commerce brings massive scale, while the crown jewel AWS boasts insane >34% margins. With its aggressive AI bets, the growth story is far from over. $1T market cap? Just the beginning!
$Microsoft(MSFT)$ just dropped a new €1B AI data center project – the uptrend is solid! The infrastructure arms race among AI giants is unstoppable. Don't jump off this train, new highs are ahead!
$Apple(AAPL)$ 's earnings are on fire, showing solid strength while other techs wobble! Its ecosystem moat is deep, and the AI+ hardware potential is huge. Holding $AAPL strong for the next leg up!
$Advanced Micro Devices(AMD)$ 's CEO projects a $1T data center chip market by 2030. With "insatiable" AI chip demand, growth is accelerating toward 35% annually. The ceiling? Nowhere in sight. Bullish!
$Novo-Nordisk A/S(NVO)$ 's market cap is back above $200B! With its blockbuster oral weight-loss drug, its leading position is solid. The market is re-rating this stock – the ceiling isn't in sight.
$iShares Biotechnology ETF(IBB)$ on fire today! Biotech rally is unstoppable - breakthrough therapies getting approved left and right. Smart money keeps piling in. Holding core positions never felt so good!
$YUNJI(02670)$ is leading the race! Its proprietary tech and early commercialization put it way ahead. Got incredibly lucky too – nailed the contra688 offer and scored SGD688 in vouchers on my first trade! With the AI boom just starting, this leader is set to fly.
$Elevance Health(ELV)$ Cut loss here due to exposed political risk that ACA might not pass Congress. If it does, I'll just buy it back. Keeping the dry powder for now.
$CoreWeave, Inc.(CRWV)$ During this round of market turbulence, I've taken the opportunity to accumulate more shares of CoreWeave following its post-earnings selloff. While the company's latest quarterly results fell short of expectations, my conviction in its long-term potential remains intact. In fact, I view this dip as a chance to strengthen my position in a company that stands at the forefront of the AI infrastructure revolution. The earnings miss was largely due to near-term challenges — mainly capacity expansion delays and higher operational expenses from scaling its data centers. These short-term headwinds, while disappointing to the market, don't change the underlying growth story. CoreWeave continues to play a pivotal role in provid